Top

Quality of Life Research

Gepubliceerd in:

01-03-2014

Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL

Auteurs: G. H. Jörgensen, A. Gardulf, M. I. Sigurdsson, S. Arnlaugsson, L. Hammarström, B. R. Ludviksson

Gepubliceerd in: Quality of Life Research | Uitgave 2/2014

Abstract

Purpose

Selective IgA deficiency (SIgAD) is the most common primary immunodeficiency with a prevalence of 1/600 in the general population. Any targeted health-related quality of life (HRQL) study of adults with SIgAD has never been presented. The objectives of the study were to compare HRQL between SIgAD adults and randomly selected age- and gender-matched population controls, and to identify risk factors for poor HRQL.

Methods

Thirty-two SIgAD individuals and 63 controls answered three questionnaires (clinical data, Short Form-36 Health Survey (SF-36), infection-related HRQL) at baseline before undergoing medical/dental examinations and laboratory assessments. HRQL in SIgAD was re-evaluated after 6 and 12 months.

Results

Baseline: Selective IgA deficiency individuals reported significantly increased fear of contracting infections (p < 0.01). Those scoring high on fear also perceived significantly poorer physical health (p < 0.01). SF-36 results indicated that SIgAD individuals perceived poorer HRQL, although this was not statistically significant. Follow-up: Compared with SF-36 responses at baseline, SIgAD individuals reported significantly more pain (p < 0.01) at 6 months, poorer general health (p < 0.05) and summarised physical HRQL (p < 0.01) at 6 and 12 months and decreased vitality at 12 months. The summarised mental scale remained stable over time. Risk factors for poor HRQL: The number of antibiotic treatments during the previous year (p < 0.001), number of daily medications (p < 0.01), allergic rhinoconjunctivitis (p < 0.05), chronic musculoskeletal symptoms at least every week (p < 0.05) and anxiety and/or insomnia (p < 0.05) were identified as independent risk factors for poor HRQL.

Conclusion

The study highlights the importance of identifying and thoroughly evaluating, educating and following up individuals with SIgAD, as their HRQL may be negatively affected due to health problems possible to prevent and treat.

vorige artikel Impact of laparoscopic colorectal segment resection on quality of life in women with deep endometriosis: one year follow-up

volgende artikel Physical activity and quality of life among university students: exploring self-efficacy, self-esteem, and affect as potential mediators

Bruton, O. C. (1952). Agammaglobulinemia. Pediatrics, 9(6), 722–728.PubMed

Al-Herz, W., Bousfiha, A., Casanova, J.-L., Chapel, H., Conley, M. E., Cunningham-Rundles, C., et al. (2011). Primary immunodeficiency diseases: An update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency. Frontiers in Immunology, 2(54). doi:10.3389/fimmu.2011.00054.

Smith, C. I. E., Ochs, H. D., & Puck, J. M. (2007). Genetically determined immunodeficiency diseases: A perspective. In H. D. Ochs, C. I. Edward Smith, & J. M. Puck (Eds.), Primary Immunodeficiency Diseases: A Molecular and Genetic Approach (2nd ed., pp. 3–15). New York: Oxford University Press.

(2013). About PI Primary Immunodeficiency (PI) affects as many as 1 million Americans and 10 million worldwide. Yet, it is just beginning to receive widespread attention. Info4PI.org Primary Immunodeficiency Resource center. Available at: http://www.info4pi.org/aboutPI/index.cfm?section=aboutPI&CFID=807672&CFTOKEN=165ae47bb16954ef-1CD0322C-0C55-E9FC-E4955D9A107D7A85. Accessed 20 Feb 15th 2013.

EU PID Consensus Document. (2013). Available at: http://www.esid.org/home.php?sub=2&id=93. Accessed 20 Feb 2013.

(2010). Deficient diagnosis. Parliament Magazine (pp. 24–25). Available at: http://www.info4pi.org/Documents/Publications/Acticle%20Parliament%20magazine_20100506_110013.pdf. Accessed 20 Feb 2013.

Fayers, P. M., & Machim, D. (2000). Quality of Life, assessment, analysis and interpretation. West Sussex: John Wiley & Sons Ltd.

Fayers, P. M., & Sprangers, M. A. (2002). Understanding self-rated health. Lancet, 359(9302), 187–188.PubMedCrossRef

The WHOQOL Group. (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychological Medicine, 28(3), 551–558.CrossRef

10.

Schipper, H., Clinch, J. J., & Olweny, C. L. M. (1996). Quality of life studies: Definitions and conceptual issues. In B. Spilker (Ed.), Quality of life and pharmacoeconomics in clinical trials (2nd ed., pp. 11–23). Philadelphia: Lippincott-Raven.

11.

Testa, M. A., & Simonson, D. C. (1996). Assessment of quality-of-life outcomes. New England Journal of Medicine, 334(13), 835–840.PubMedCrossRef

12.

Gardulf, A., Björvell, H., Gustafson, R., Hammarström, L., & Smith, C. I. E. (1993). The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clinical and Experimental Immunology, 92(2), 200–204.PubMedCentralPubMedCrossRef

13.

Gardulf, A., & Nicolay, U. (2006). Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Current opinion in Allergy and Clinical Immunology, 6(6), 434–442.PubMedCrossRef

14.

Zebracki, K., Palermo, T. M., Hostoffer, R., Duff, K., & Drotar, D. (2004). Health-related quality of life of children with primary immunodeficiency disease: A comparison study. Annals of Allergy, Asthma & Immunology, 93(6), 557–561.CrossRef

15.

Fasth, A., & Nyström, J. (2008). Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. Journal of Clinical Immunology, 28(4), 370–378.PubMedCrossRef

16.

Mozaffari, H., Pourpak, Z., Pourseyed, S., Moin, M., Farhoodi, A., Aghamohammadi, A., et al. (2006). Health-related quality of life in primary immune deficient patients. Iranian Journal of Allergy, Asthma and Immunology, 5(1), 23–27.

17.

Winkelstein, J. A., Conley, M. E., James, C., Howard, V., & Boyle, J. (2008). Adults with X-linked agammaglobulinemia: impact of disease on daily lives, quality of life, educational and socioeconomic status, knowledge of inheritance, and reproductive attitudes. Medicine (Baltimore), 87(5), 253–258.CrossRef

18.

Aghamohammadi, A., Montazeri, A., Abolhassani, H., Saroukhani, S., Pourjabbar, S., Tavassoli, M., et al. (2011). Health-related quality of life in primary antibody deficiency. Iranian Journal of Allergy, Asthma and Immunology, 10(1), 47–51.

19.

Berger, M., Murphy, E., Riley, P., & Bergman, G. E. (2010). Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. Southern Medical Journal, 103(9), 856–863.PubMedCrossRef

20.

Hoffmann, F., Grimbacher, B., Thiel, J., Peter, H. H., & Belohradsky, B. H. (2010). Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. European Journal of Medical Research, 15(6), 238–245.PubMedCentralPubMed

21.

Soresina, A., Nacinovich, R., Bomba, M., Cassani, M., Molinaro, A., Sciotto, A., et al. (2009). The quality of life of children and adolescents with X-linked agammaglobulinemia. Journal of Clinical Immunology, 29(4), 501–507.PubMedCrossRef

22.

Borte, M., Bernatowska, E., Ochs, H. D., Roifman, C. M., & The Vivaglobin Study Group. (2011). Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clinical and Experimental Immunology, 164(3), 357–364.PubMedCentralPubMedCrossRef

23.

Modell, V., Gee, B., Lewis, D. B., Orange, J. S., Roifman, C. M., Routes, J. M., et al. (2011). Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: An updated report from the Jeffrey Modell Foundation. Immunologic Research, 51(1), 61–70.PubMedCrossRef

24.

Nicolay, U., Haag, S., Eichmann, F., Herget, S., Spruck, D., & Gardulf, A. (2005). Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Quality of Life Research, 14(7), 1683–1691.PubMedCrossRef

25.

Sigstad, H. M., Stray-Pedersen, A., & Frøland, S. S. (2005). Coping, quality of life, and hope in adults with primary antibody deficiencies. Health and Quality of Life Outcomes, 3, 31.PubMedCentralPubMedCrossRef

26.

Gardulf, A., Borte, M., Ochs, H. D., Nicolay, U., & Group, V. C. S. Vivaglobin Clinical Study Group. (2008). Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clinical Immunology, 126(1), 81–88.PubMedCrossRef

27.

Gardulf, A., Nicolay, U., Math, D., Asensio, O., Bernatowska, E., Böck, A., et al. (2004). Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. The Journal of Allergy and Clinical Immunology, 114(4), 936–942.PubMedCrossRef

28.

Nicolay, U., Kiessling, P., Berger, M., Gupta, S., Yel, L., Roifman, C. M., et al. (2006). Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. Journal of Clinical Immunology, 26(1), 65–72.PubMedCrossRef

29.

Hammarström, L., & Edvard Smith, C. I. (2007). Genetic approach to common variable immunodeficiency and IgA deficiency. In H. D. Ochs, C. I. Edward Smith, & J. M. Puck (Eds.), Primary immunodeficiency diseases: A molecular and genetic approach (2nd ed., pp. 313–325). New York: Oxford University Press.

30.

(2013). Diagnostic criteria for PID. European Society for Immunodeficiencies. Available at: http://www.esid.org./clinical-diagnostic-criteria-for-pid-73-0#Q7www.esid.org. Accessed 20 Feb 2013.

31.

Woof, J. M., & Ken, M. A. (2006). The function of immunoglobulin A in immunity. Journal of Pathology, 208(2), 270–282.PubMedCrossRef

32.

Rockey, J. H., Hanson, L. Å., Heremans, J. F., & Kunkel, H. G. (1964). β2A aglobulinemia in two healthy men. Journal of Laboratory and Clinical Medicine, 63, 205–212.PubMed

33.

Ammann, A. J., & Hong, R. (1971). Selective IgA deficiency: Presentation of 30 cases and a review of the literature. Medicine (Baltimore), 50(3), 223–236.CrossRef

34.

Koistinen, J. (1975). Selective IgA deficiency in blood donors. Vox Sanguinis, 29(3), 192–202.PubMedCrossRef

35.

Ulfarsson, J., Gudmundsson, S., & Birgisdottir, B. (1982). Selective serum IgA deficiency in Icelanders. Frequency, family studies and Ig levels. Acta Medica scandinavica, 211(6), 481–487.PubMedCrossRef

36.

Litzman, J., Sevcikova, I., Stikarovska, D., Pikulova, Z., Pazdirkova, A., & Lokaj, J. (2000). IgA deficiency in Czech healthy individuals and selected patient groups. International Archives of Allergy and Immunology, 123(2), 177–180.PubMedCrossRef

37.

Liblau, R. S., & Bach, J.-F. (1992). Selective IgA deficiency and autoimmunity. International Archives of Allergy and Immunology, 99(1), 16–27.PubMedCrossRef

38.

Aghamohammadi, A., Cheraghi, T., Gharagozlou, M., Movahedi, M., Rezaei, N., Yeganeh, M., et al. (2009). IgA deficiency: Correlation between clinical and immunological phenotypes. Journal of Clinical Immunology, 29(1), 130–136.PubMedCrossRef

39.

Edwards, E., Razvi, S., & Cunningham-Rundles, C. (2004). IgA deficiency: Clinical correlates and responses to pneumococcal vaccine. Clinical Immunology, 111(1), 93–97.PubMedCrossRef

40.

Yel, L. (2010). Selective IgA deficiency. Journal of Clinical Immunology, 30(1), 10–16.PubMedCentralPubMedCrossRef

41.

Jorgensen, G. H., Gardulf, A., Sigurdsson, M. I., Sigurdardottir, T. S., Thorsteinsdottir, I., Gudmundsson, S., et al. (2013). Clinical symptoms in adults with selective IgA deficiency: A case-control study. Journal of Clinical Immunology, 33(4), 742–747.PubMedCrossRef

42.

Gardulf, A. (1994). Rapid subcutaneous immunoglobulin replacement therapy in patients with primary antibody deficiency: Aspects of effectiveness safety, home-therapy, quality of life and costs. PhD-thesis, Karolinska Institutet, Stockholm. ISBN no 91-628-1403-6.

43.

Ware, J. E., Jr., Snow, K. K., Kosinski, M., Gandek, B. (1993, 2000). SF-36 ^® Health Survey: Manual and interpretation guide. Lincoln, RI: QualityMetric Incorporated.

44.

Ware, J. E, Jr, & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.PubMedCrossRef

45.

Marquis, P., Chassany, O., & Abetz, L. (2004). A comprehensive strategy for the interpretation of quality-of-life data based on existing methods. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 7(1), 93–104.CrossRef

46.

Ware, J. E, Jr. (2000). SF-36 health survey update. Spine, 25(24), 3130–3139.PubMedCrossRef

47.

Gardulf, A., Hansen, S., Elnerson, K., Ericson, E., Fust, R., Hagstedt, C., et al. (2007). In Swedish. [The SwePID Study; To live with a primary immunodeficiency. Report regarding adults]. Available at http://ki.se/ki/jsp/polopoly.jsp?d=16775&l=en. Stockholm: Karolinska Institutet.

48.

Jorgensen, G. H., Arnlaugsson, S., Theodors, A., & Ludviksson, B. R. (2010). Immunoglobulin a deficiency and oral health status: A case-control study. Journal of Clinical Periodontology, 37(1), 1–8.PubMedCrossRef

49.

Jorgensen, G. H., Thorsteinsdottir, I., Gudmundsson, S., Hammarstrom, L., & Ludviksson, B. R. (2009). Familial aggregation of IgAD and autoimmunity. Clinical Immunology, 131(2), 233–239.PubMedCrossRef

50.

Howard, V., Greene, J. M., Pahwa, S., Winkelstein, J. A., Boyle, J. M., Kocak, M., et al. (2006). The health status and quality of life of adults with X-linked agammaglobulinemia. Clinical Immunology, 118(2–3), 201–208.PubMedCrossRef

51.

Gustafson, R., Gardulf, A., Granert, C., Hansen, S., & Hammarstrom, L. (1997). Prophylactic therapy for selective IgA deficiency. Lancet, 350(9081), 865.PubMedCrossRef

52.

Leong, K. P., Yeak, S. C., Saurajen, A. S., Mok, P. K., Earnest, A., Siow, J. K., et al. (2005). Why generic and disease-specific quality-of-life instruments should be used together for the evaluation of patients with persistent allergic rhinitis. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology, 35(3), 288–298.CrossRef

53.

Ferreira, R. C., Pan-Hammarström, Q., Graham, R. R., Gateva, V., Fontan, G., Lee, A. T., et al. (2010). Association of IFIH1 and other autoimmunity risk alleles with selective IgA deficiency. Nature Genetics, 42(9), 777–780.PubMedCrossRef

54.

Dembo, T., Leviton, G. L., & Wright, B. A. (1956). Adjustment to misfortune; A problem of social-psychological rehabilitation. Artificial Limbs, 3(2), 4–62.PubMed

Titel: Health-related quality of life (HRQL) in immunodeficient adults with selective IgA deficiency compared with age- and gender-matched controls and identification of risk factors for poor HRQL
Auteurs: G. H. Jörgensen
A. Gardulf
M. I. Sigurdsson
S. Arnlaugsson
L. Hammarström
B. R. Ludviksson
Publicatiedatum: 01-03-2014
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 2/2014
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-013-0491-9

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 2/2014

Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO

Assessment of children’s own health status using visual analogue scale and descriptive system of the EQ-5D-Y: linkage between two systems

Sleep characteristics and health-related quality of life among a national sample of American young adults: assessment of possible health disparities

Metacognition: towards a new approach to quality of life

Comparative validation of the WOMAC osteoarthritis and Lequesne algofunctional indices in Greek patients with hip or knee osteoarthritis

Physical activity and quality of life among university students: exploring self-efficacy, self-esteem, and affect as potential mediators